Two of the 31 patients were removed from the current study because of toxicity (fatigue). However, dose reductions or short breaks from the drug were required for most patients, usually due to hypertension, diarrhea and fatigue.
By analyzing blood samples from patients, the researchers found that the biomarkers FGF (fibroblast growth factor) and Tie-2 were associated with tumor progression and could be used to predict treatment failure in this study population, Batchelor says. FGF is a protein tied to new blood vessel growth; Tie-2 is a receptor that binds to and is activated by the angiopoietins protein growth factors required for the formation of blood vessels.
Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer: LB304
Adding bevacizumab to standard chemotherapy and radiation in patients with rectal cancer fully prevented tumor spread and normalized tumor blood vessels enough to enable effective therapy, researchers report.
I know of no other therapy in this patient population where we can even get close to 100 percent tumor control. Although this needs to be confirmed in a randomized trial against a placebo group, these are very impressive numbers, said Rakesh Jain, Ph.D., Andrew Werk Professor of Tumor Biology at Harvard Medical School.
Bevacizumab is currently approved for colorectal cancer, and works by destroying the blood vessels that tumors need to grow.
This mechanism of action was a conundrum for scientists because in order for radiation and chemotherap
'/>"/>
| Contact: Staci Vernick Goldberg Staci.goldberg@aacr.org 267-646-0616 American Association for Cancer Research Source:Eurekalert |